HCW Biologics ^{Priced, Nasdaq: HCWB}

We are an innovative clinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. We believe age-related low-grade chronic inflammation, or “inflammaging,” is a significant contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative disease, and autoimmune disease. We believe our approach has the potential to provide an innovative treatment of these age-related diseases. Our gateway indication is oncology. By the end of 2021, we expect to have four active clinical trials to evaluate our molecules for cancer indications. There are currently two ongoing Phase 2 clinical trials to evaluate our molecule, HCW9201, in a cell based therapy treatment for generation of ML-NK cell products for patients with relapsed / refractory acute myeloid leukemia (“r/r AML”). We developed the protocol in conjunction with the sponsor, Washington University, and have licensed limited rights for ex vivo use of this molecule to Wugen Inc.